153836-14-7 Usage
General Description
Tert-butyl 4-carbamimidoylpiperazine-1-carboxylate is a chemical compound with the molecular formula C11H19N5O2. It is a derivative of piperazine and contains a tert-butyl group and a carbamimidoyl group. Tert-butyl 4-carbamimidoylpiperazine-1-carboxylate is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various compounds, including potential pharmaceutical agents. It may have potential applications in the development of drugs for various medical conditions. The chemical structure of Tert-butyl 4-carbamimidoylpiperazine-1-carboxylate makes it a valuable intermediate for the synthesis of complex molecules with potential biological activity.
Check Digit Verification of cas no
The CAS Registry Mumber 153836-14-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,8,3 and 6 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 153836-14:
(8*1)+(7*5)+(6*3)+(5*8)+(4*3)+(3*6)+(2*1)+(1*4)=137
137 % 10 = 7
So 153836-14-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N4O2/c1-10(2,3)16-9(15)14-6-4-13(5-7-14)8(11)12/h4-7H2,1-3H3,(H3,11,12)
153836-14-7Relevant articles and documents
PYRIDOPYRIMIDINES AND METHODS OF THEIR USE
-
Page/Page column 78; 79, (2021/12/28)
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
HEPATITIS B VIRAL ASSEMBLY EFFECTORS
-
Paragraph 00332, (2016/10/31)
Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
